Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6531
    +0.0031 (+0.47%)
     
  • OIL

    82.99
    +0.18 (+0.22%)
     
  • GOLD

    2,341.20
    +2.80 (+0.12%)
     
  • Bitcoin AUD

    97,582.09
    -4,336.86 (-4.26%)
     
  • CMC Crypto 200

    1,360.27
    -22.31 (-1.61%)
     
  • AUD/EUR

    0.6091
    +0.0021 (+0.34%)
     
  • AUD/NZD

    1.0957
    +0.0016 (+0.14%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,096.40
    +56.02 (+0.70%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,979.60
    -109.10 (-0.60%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Why Shares of Provention Bio Went Up 30.3% in November

Why Shares of Provention Bio Went Up 30.3% in November

Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.